Antidote Technologies is teaming up with SEQSTER to streamline patient identification for clinical trials and improve trial timelines. Antidote’s patient-recruitment platform will use SEQSTER’s healthcare data platform to match patients to trials based on their genetic, lifestyle, and medical data. The partnership aims to accelerate the recruitment process and bring new treatments to market faster. This collaboration is part of a larger trend in the industry, with companies like Atropos Health, Thread, and Flatiron Health also focusing on improving the clinical trial experience and access to trials for patients. Other players in the space include Inato, DiMe, Science 37, and Paradigm.
Source link
SEQSTER partners with Antidote Technologies for clinical trial enrollment
